完全可吸收封堵器——结构性和先天性心脏病治疗的关键进展?  

Fully bioabsorbable devices-key development in the treatment of structural and congenital heart disease?

作　　者：Kerstin Piayda Stefan Bertog Kolja Sievert Horst Sievert 

机构地区：[1]CardioVascular Center Frankfurt,Frankfurt 60389,Germany [2]Department of Cardiology and Angiology,Universitätsklinikum Gieûen und Marburg,Gieûen 35391,Germany

出　　处：《Science Bulletin》2023年第16期1733-1734,共2页科学通报（英文版）

摘　　要：Over the past decades,transcatheter therapy has become the primary option for the treatment of simple congenital heart diseases with the advantages of minimal invasiveness and rapid recovery.However,currently used metal occluders may cause nickel allergies,inflammation,and erosion.In the treatment of ventricular septal defects(VSD),due to the close proximity of the electrical conduction tissue,implantation of conventional occluders may cause conduction abnormalities.Complete atrioventricular block can occur in up to 2%of patients undergoing percutaneous perimembranous VSD closure with conventional devices[1].The timing of this event varies,ranging from immediate/intraprocedural to years after the procedure.Most commonly,it is observed within the first five days[1],however,late-onset atrioventricular block is fairly common.For this reason,no perimembranous VSD closure device has been approved by the US Food and Drug Administration[2].The complicated anatomical structure of VSDs and its anatomical relationship to the atrioventricular node complicates device design and development.In this context,bioresorbable occluders have potential advantages.It is conceivable that,due to implant degradation over time and native cardiac tissue coverage,surrounding tissue compression and persistent arrhythmias are less prevalent.

关 键 词：先天性心脏病 CLOSURE conduction 

分 类 号：R541[医药卫生—心血管疾病]